[Effects of glucagon-like peptide 2 on the adaptation of residual small bowel in a rat model of short bowel syndrome].
OBJECTIVE
To investigate the effects of glucagon-like peptide 2 (GLP-2) on the morphology and functional adaptation of the residual small bowel in rat model of short bowel syndrome.


METHODS
Twenty rats with 75% of the midjejunoileum removed were randomly divided into two groups, and received intra-peritoneal injection of GLP-2(250 micro*gd*kg-1*d-1) or subcutaneous injection saline(0.5 ml, twice one day) after operation. On postoperative day 6, the morphological changes of the residual jejunum and ileum, the expression of proliferating cell nuclear antigen(PCNA), and the mRNA expressions of Na-D-glucose cotransporters (SGLT1) and peptide cotransporters (PEPT1) were determined. The intestinal glucose absorption data per unit length as well as per unit weight of ileum were measured by in vivo circulatory perfusion experiment.


RESULTS
The morphological parameters of the residual gut such as the thickness of mucosa, height of villus, depth of crypt, and PCNA positive index were significantly higher, while the apoptosis rate per unit of mucosal square was significantly lower in GLP-2 treatment group than those in the control group. The expressions of mRNA SGTLl and PEPT1 in the residual ileum were significantly higher than those in the control group. There was no significant difference in glucose absorption rate per gram of mucosal wet weight between the two groups (P > 0.05).


CONCLUSIONS
GLP-2 could improve morphological and functional adaptation of the residual small bowel by stimulating enterocyte proliferation and decreasing enterocyte apoptosis in short bowel syndrome.
Wu
Guo-Hao
GH
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. prowugh@yahoo.com.cn
Chen
Ji
J
Li
Hang
H
Wu
Zhao-Han
ZH
D000818:Animals; D004195:Disease Models, Animal; D053767:Glucagon-Like Peptide 2 / Q000627:therapeutic use*; D007082:Ileum / Q000473:pathology; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D007421:Intestine, Small / Q000601:surgery; D008297:Male; D011183:Postoperative Complications / Q000628:therapy*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012778:Short Bowel Syndrome / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*
D053767:Glucagon-Like Peptide 2; D018809:Proliferating Cell Nuclear Antigen